Schiller, D.S. and Fung, H.B. (2007) Posaconazole An extended spectrum triazole antifungal agent. Clinical Th- erapeutics, 29(9), 1862-1886. - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

Schiller, D.S. and Fung, H.B. (2007) Posaconazole: An extended spectrum triazole antifungal agent. Clinical Th- erapeutics, 29(9), 1862-1886.

has been cited by the following article:

TITLE: Treatment of chronic vulvovaginal candidiasis with posaconazole and ciclopiroxolamine

AUTHORS: Hans-Jürgen Tietz

KEYWORDS: Chronic Recurrent Vulvovaginal Candidiasis; VVC; Candida Glabrata; Posaconazole

JOURNAL NAME: Health, Vol.2 No.6, June 28, 2010

ABSTRACT: Therapy of chronic recurrent vulvovaginal can- didiasis (VVC) caused by Candida glabrata is still rare in comparison to C. albicans infection, but therapy remains more difficult. Combination therapy with topical antifungals may improve therapy outcome, but still standard agents as fluconazole or itraconazole often fail. Posaconazole is a new systemic triazole with a wide antifungal spectrum including rare Candida species. Up to now, no clinical trials with posa- conazole in chronic recurrent VVC have been undertaken. Here, first results of the application of a new therapy regimen consisting of oral posaconazole in combination with topical ciclopiroxolamine are presented. 15 patients with chronic recurrent VVC caused by C. glabrata have been treated. 14 of these patients experienced successful therapy, clinical and mycological cure 30 days after begin of therapy has been observed. Long-term results are promising, as in 4 patients clinical and mycologic cure persists for more than 1 year up to now.

Open Access

Molecular Characterization of Extended Spectrum β-Lactamase Genes in Clinical E. coli Isolates

James Chibueze Igwe, Josiah Ademola Onaolapo, Mohammed Kachallah, Amose Nworie, Hannah Oluwakemi Oladipo, Beatrice Onyiye Ojiego, Obadiah Dauda Enose, Seyi Ebun Adeboye, Mojirayo Titilayo Durowaiye, Alex Uwadiegwu Akpa, Inimfon Akaninyene Ibanga

DOI: 10.4236/jbise.2014.75030 4,137 Downloads 6,114 Views Citations

Pub. Date: April 11, 2014

Open Access

Low Prevalence of Carbapenem Resistance in Clinical Isolates of Extended Spectrum Beta Lactamase (ESBL) Producing Escherichia coli in North Central, Nigeria

Kenneth I. Onyedibe, Emmanuel O. Shobowale, Mark O. Okolo, Michael O. Iroezindu, Tolulope O. Afolaranmi, Francisca O. Nwaokorie, Solomon O. Opajobi, Samson E. Isa, Daniel Z. Egah

DOI: 10.4236/aid.2018.83011 662 Downloads 1,242 Views Citations

Pub. Date: August 13, 2018

Open Access

Children with Down Syndrome (DS), and Autism Spectrum Disorder (ASD): Difficulties of Screening and Management of This Dual Diagnosis about 3 Cases

Khaoula Mammad, Meryem Chkirat, Yamna Kriouile, Asmaa Mdaghri Alaoui

DOI: 10.4236/psych.2019.106060 802 Downloads 1,480 Views Citations

Pub. Date: May 30, 2019

Open Access

Characterization of Ciprofloxacin resistant Extended Spectrum β-Lactamase (ESBL) producing Escherichia spp. from clinical waste water in Bangladesh

Nihad Adnan, Munawar Sultana, Ovinu Kibria Islam, Shuvro Prokash Nandi, M. Anwar Hossain

DOI: 10.4236/abb.2013.47A2003 3,965 Downloads 6,836 Views Citations

Pub. Date: July 10, 2013